Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7691552 | 1.00 | L3MBTL1 (0.77) | L3MBTL1PPARAPLA2G4BFFAR4ALB | |
| SCHEMBL29335714 | 1.00 | L3MBTL1 (0.77) | L3MBTL1PPARAPLA2G4BFFAR4ALB | |
| SCHEMBL8357754 | 1.00 | L3MBTL1 (0.77) | L3MBTL1PPARAPLA2G4BFFAR4ALB | |
| SCHEMBL14570555 | 1.00 | L3MBTL1 (0.77) | L3MBTL1PPARAPLA2G4BFFAR4ALB | |
| SCHEMBL4257143 | 0.98 | L3MBTL1 (0.79) | L3MBTL1PPARAPLA2G4BFFAR4ALB | |
| SCHEMBL6883728 | 0.93 | L3MBTL1 (0.82) | L3MBTL1PPARAPLA2G4BFFAR4TSHR | |
| SCHEMBL31448424 | 0.91 | PPARA (0.71) | L3MBTL1PPARAPLA2G4BALBGAA | |
| SCHEMBL29141429 | 0.91 | PPARA (0.71) | L3MBTL1PPARAPLA2G4BALBGAA | |
| SCHEMBL21073528 | 0.91 | PPARA (0.71) | L3MBTL1PPARAPLA2G4BALBGAA | |
| SCHEMBL31448470 | 0.89 | PPARA (0.73) | L3MBTL1PPARAPLA2G4BALBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | L3MBTL1 1690/4885PPARA 219/4885PLA2G4B 24/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | L3MBTL1 1923/4885PPARA 333/4885PLA2G4B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.